LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOC 263/204 APPLICANT:

Chris Small et al.

SERIAL NO.

Not yet assigned 64/85 2,066

(Use several sheets if necessary)

FILING DATE: Herewith 5/8/01 GROUP: /6 3

	U.S. PATENT DOCUMENTS						
EXAMINER INITIAI		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
pid 7	AA	4,693,971	9/15/87	Misaki			
	AB	4,698,299	10/6/87	Janoff et al.			
	AC	4,784,945	11/15/88	Artiss et al.			
	AD	5,122,454	6/16/92	Ueda et al.			
	AE	5,277,917	1/11/94	Xu et al.			
	AF	5,326,690	7/5/94	Xu et al.			
<u> </u>	AG	5,489,580	2/6/96	Markiyannis et al.			

	FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS	NO
• • • •	АН .	210691	3/31/07	German				
	AI	882.048	9/4/80	Belgium				
	AJ	63-13644	1/20/88	Japan				
mil	AK.	WO 89/01773	3/9/89	PCT				
RLF (AL AL	EP 0 322 262	6/28/89	EPO				
15.	AM •	2-107195	4/19/90	Japan				Campaga ang
min	I_{AN} .	WO 90/10448	9/20/90	PCT				
mo	AO	WO 93/11136	6/10/93	PCT				
The state of the s	AP	8-53475	2/27/96	Japan				
12200	AQ	WO 97/45727	4/12/97	PCT				

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
mr JAR	Asaoka et al., (1992) "Role of lysophosphatidlycholine in T-lymphocyte activation: Involvement of phospholipase A ₂ in signal transduction through protein kinase C," Proc. Natl Acad. Sci. USA 89:6447-6451
in as	Asaoka et al., (1993) Proc. Natl Acad. Sci. USA 90:4917-4921

OC-79515.1EXAMINER: Not Yet Assigned

MG Foran

DATE CONSIDERED: 4/11/6 3

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOC	SERIAL NO.
263/204	Not yet assigned
APPLICANT: Chris Small et al.	t 9/852,066
FILING DATE:	GROUP: 1631
Herewith 5/5/01	Not Yet Assigned

Herewith 5/5/01

(Use several sheets if necessary)

		Bligh and Dyer, (1950) "A rapid method of total lipid extraction and purification," Can. J. Biochem. Physiol.
7/4/17	AT "	27/0/011-017
1.11	A1	Bowes et al. (1993) "The Acquisition of Lysophosphatidylcholine by African Trypanosomes," J. Biol. Chem.
144	AUω	269/10/12995 13997
	,	Creer and Gross; (1985), "Separation of Isomeric Lysophospholipids by Reverse Phase HPLC," Lipids
10/2 in 167	AV	20(12) 022 029
* 1k	***	Domansky, V. (1992) "Functional condition and phospholipid profile of red blood cells in breast cancer patients,
in A	AW J	Vopr. Onkol. 38(10):1194—1202 (English and Russian translations provided)
	1	
man	'AX	Dorum et al. (1996) "Early detection of familial ovarian cancer," E. J. Cancer 32A(10):1645-1651
. (9		Einhorn et al., (1992) "Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer,"
Int.	AY	Obstat Gymacol 80(1):14-18
		Fleming et al., "Assessman of phosphatidylcholine, lysophosphatidylcholine, and sphingelomyelin in human
MY	AZ •	$v_{col} = D_{col}^{*} - 1_{col} = 20(4) \cdot 240 \cdot 256 \cdot (1087)$
	1	Fukami et al. (1988), "Antibody to phosphatidylinositol 4,5-bisphosphate inhibits oncogene-induced mitogenesis,"
per 17 per 17 per 17	BA	D N-4 A-4 Col UCA 95:0057 0061
111	,	Gaudette et al. (1993), "Mass and fatty acid composition of the 3-phosphorylatd phosphatidylinositol bisphosphate
N. T	BB	isomer in stimulated human platelets," J. Biol. Chem. 268(19): 13773-13776
. , , ,		Gillet et al (1975), "Plasma concentrations of lysolecithin and other phospholipids in the healthy population and in
mil	BC '_	men suffering from atherosclerotic diseases" Atherosclerosis 22:111-124
MAT	BD ,	Gregor Cevc, ed., "Phospholipids Handbook," Ch. 28: Gupta "Phospholipids in Disease," pp. 895-908(1993)
		Hara et al. (1996), "Lysophosphatidylserine Enhances Exogenous Type II Phosphoshpase Ny-Induced Petration
	BE `	- Charles Carosal Mast Call "Riol Pharm Rull 19(3)"4/4-4/6
		Higashiyama et al, "A Heparin-Binding Growth Factor Secreted by Macrophase-Like Cells that is Related to
Ì	BF	EGF," Science 251:936-939
		for exercism concert Feb. 6, 1988 Vol 268-271
	BG '	Jacobs et al (1988), "Multimodal approach to screening for ovarian cancer," Lancet Feb. 6, 1988 Vol 268-271
	,	Jacobs et al (1988), Multimodar approach to screening for a state of the s
	BH	cohort study," BMJ 313:1355-1358 Jalink et al (1994), "Growth factor-like effects of lysophosphatidic acid, a novel lipid mediator," Biochim.
		Jalink et al (1994), "Growth factor-like effects of lysophosphatique acid, a novel lipid mediator,"
	BI	Biophys. Acta 1198:185-1976 Kalnova (1989), "Relationship between antioxidant activity and lipid profile of blood as marker of the effect of
		tumor on the host," Vopr. Onkol. 35(7):785-801 (English and Russian translations provided)
	BJ	Kawasaki et al (1989), "Determination of Inorganic Phosphate by Flow Injection Method with Immobilized
	DT/	Enzymes and Chemiluminescence Detection," Analytical Biochem. 182:366-370
	BK	Keating et al (1996), "Inhibition of protein synthesis in frog (Xenopus Laevis) egg extracts by an antibody against
	DI 7	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
<u> </u>	BL ,	Kriat et al (1993), "Analysis of plasma lipids by NMR spectroscopy: Application to modifications induced by
	DM.	11: mand tamore " I I inid Res 34:1009-1019
	BM "	Kume and Gimbrone (1994), "Lysophosphatidylcholine transcriptionally induces growth factor gene expression in
	DNI '	cultured human endothelial cells," J. Clin. Invest. 93:907-911
	BN	
	BO .	Lehninger, Biochemistry 2 nd edition, pp 290-291, Worth Publishers, Inc. New York (1975) No month found
		Librat and Markon (1995) "Ca2" Influx. Phosphoinositide Hydrolysis, and Histamine Release induced by
	BP Y	Lysophosphatidylserine in Mast Cells," J. Cell. Physiol. 165(1):89-95
L	101	

OC-79515.1EXAMINER:	111111	DATE CONSIDERED:
Not Yet Assigned	My i to can	// // Land AADED 600
EVALUATED Initial if	reference is considered whether (or not citation is in conformance with MPEP 609;

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOC	SERIAL NO.
263/204	Not yet assigned
APPLICANT:	09/852,666
Chris Small et al.	10027
FILING DATE:	CROUP: //o ×/

Herewith

(Use several sheets if necessary)

		- + ql.
		Lloret and Moreno (1994), "Immunochemical relatednes between secretory phospholipase A2 and intracellular
71.42	BQ '	phospholipase A ₂ activity linked with arachidonic acid and mobilization in macrophages," Toxicon 32 (11):1327-1336
1	BR '	Matuoka et al (1988), "Mitogenesis in response to PDGF and bombesin abolished by microinjection of antibody to PIP ₂ ," Science 239:640-643
	BS ;	Mills et al (1988), "A putative new growth factor in ascitic fluid from ovarian cancer patients: Identification; characterization, and mechanism of action," Cancer Research 48:1066-1071
	BT	Mills et al (1990), "Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells,": J. Clin. Invest. 86:851-855
	BU,	
	ВС	Moolenaar (1995), "Lysophosphatidic acid signalling," Current Opinion in Cell. Biol. 7:203-210 'Moolenaar (1992), "Lysophosphatidic acid: A bioactive phospholipid with growth factor-like properties," Rev.
	BV "	Physiol. Biochem. Pharamcol. 119:47-65
	BW c'	Muto et al (1993), "Screening for Ovarian Cancer: The preliminary experience of a familial ovarian cancer center," Gynecologic Oncol. 51:12-20
	BX .	Nakano et al (1994), "Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes," Proc. Natl Acad. Sci USA 91:1069-1073
	BY .	Ogawa (1997), "Group II Phospholipase A ₂ in Neoplastic Disease," In: Phospholipase A: Basic and Clinical Aspects in Inflammatory Diseases, Uhl et al Eds. Vol 24, pp. 200-204.
	0	Okita et al (1997), "Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine
	BZ	(LYSOPC) in ovarian cancer patients," Int. J. Cancer 71:31-34
	CA *	Panetti et al (1997), "Endothelial cell mitogenesis induced by LPA: Inhibition by thrombospondin-1 and thrombospondin-2," J. Lab. Clin. Med. 129(2):208-216
	СВ	Phillips et al (1967), "Composition of phospholipids and of phospholipid fatty acids of human plasma," J. Lipid Res. 8:676-681
	CC .	Racenis et al (1992), "The Acyl Dihydroxyacetone Phosphate Pathway Enzymes for Glycerolipid Biosynthesis are Present in the Yeaset Saccharomyces cerevisiae," J. Bacteriol. 174:5702-5710
	CD ,	Resnick and Tomaska (1994), "Stimulation of Yeast Adenylyl Cyclase Activity by Lysophospholipids and Fatty Acids," J. Biol. Chem. 269(51)"32336-32341
	CE '	Ross (1993) "The pathogenesis of atherosclerosis" A perspective for the 1990s," Nature (London) 362:801-809
	CF '	Sasaki et al (1993) "Potentiation of diacylglycerol-induced activation of protein kinase C by lysophospholipids," FEBS Letters 320(1):47-51
	CG '	Schapira et al (1993), "The effectiveness of ovarian cancer screening: A decision analysis model," Ann. Intern. Med. 118(11):838-843
		Schrier et al (1996), "The Effects of Phospholipase A ₂ Inhibitor, Manoalide, on Cartilate Degradation, Stromelysin
	СН	Expression, and Synovial Fluid Cell Count Induced by Intraarticular Injection of Human Recombinant Interleukin- 1α in the Rabbit," Arthritis Rheum. 39(8):1292-1299
	<u> </u>	Shen et al. (1997), "Evaluation of lysophosphatidic acid (LPA) as a diagnostic marker for ovarian cancer and other
	CI .	gynecological cancers," Clinical Chemistry 43(6):S230
	′.	Skeaff et al (1987); "Effect of dietary fish oil containing eicosapentaenoic acid on the fatty acid composition of
:	CJ	platelet phospholipids and on the thrombin-stimulated phospholipid alterations in human platelets," Collogue INSERM 152:63-76
, /	CK ·	Skipski et al (1967), "Lipid composition of human serum lipoproteins," Biochem J. 104:340-352
		Steinberg et al (1989), "Beyond cholesterol: Modifications of low-density lipoprotein that increase its
\vee	CL .	atherogenicity," N. Eng. J. Med. 320(14):915-924

OC-79515.1EXAMINER: 447, 47	DATE CONSIDERED:	/ -
Not Yet Assigned 19 4 14 10	4/1	11/6 3

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

INFORMATION DISCLOSURE STATEMENT

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S

(Use several sheets if necessary)

ATTY. DOO SERIAL NO. 263/204 Not yet assigned 04/05 2,066 **APPLICANT:** Chris Small et al. GROUP: 1631 **FILING DATE:**

Not Yet Assigned

LUYM	CM	Tamori-Natori et al. (1986), "Metabolism of Lysophosphatidylserine, a Potentiator of Histamine Release in Rat Mast Cells," J. Biochem (Tokyo) 100(3):581-590
	CN	Thomas et al (1991), "Eicosanoid-dependent and –independent formation of individual [14C]stearoyl-labeled lysophospholipids in collagen-stimulated human platelets," Biochim. Biophys. Acta 1081:92-98
	co.	Tigyi et al (1994), "Lysophosphatidic acid possesses dual action in cell proliferation," Proc natl Acad Sci USA. 91:1908-1912
	СР	Tokumura et al (1986), "Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma," Biochim Biophys. Acta 875:31-38
	CQ	Tramposch et al (1994), "Inhibitor of Phospholipase A ₂ Blocks Eicosanoid and Platelet Activating Factor Biosynthesis and Has Topical Anti-Inflammatory Activity," J. Pharmacol. And Experimental Therapeutics 271(2):852-859
	CR >	Van den Bosch et al (1974), "Phosphoglyceride Metabolism," Ann. Rev. Biochem. 43:243-277
	CS	Vogt (1960), "Darmerregende Activität verschiedener Phosphatide und Glykolipide," Arch. Pathol. Pharmakol 240:124-139
	СТ	Xu et al (1995), "Lysophospholipids activate ovarian and breast cancer cells," Biochem J. 309:933-940
	CU '	Xu et al (1995), "Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients," Clin. Cancer Res. 1:1223-1232
\/	CV Č	Xu et al (1995) "Effect of Lysophospholipids on Signaling in the Human Jurkat T Cell Line," J. Cell Physiol 163:441-450
V	CW.	Yoshida et al (1992), "Platelet activation by simultaneous actions of diacylglycerol and unsaturated fatty acids," Proc. Natl. Acad. Sci. USA 89:6443-6446

Herewith

DATE CONSIDERED: 4/11/0 3 OC-79515.1EXAMINER: MG when Not Yet Assigned

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant